Displaying 21–30 of 347 diseases results
Nov 18, 2022
Editas Reports Results for 14 Participants in its Phase 1/2 CRISPR/Cas9 Clinical Trial for LCA10
The company is seeking a partner to move the LCA10 program forward
Nov 14, 2022
Chloe’s Creative Journey with Vision Loss
Chloé Duplessis is a legally blind digital collage artist in Denver, Colorado. At 39 years old, Chloé was diagnosed with Stargardt disease, which was a pivotal point in her creative journey to becoming a full-time artist and owner of Duplessis Art.
Nov 10, 2022
Foundation Launching its Largest Natural History Study to Date for 1,500 People with Inherited Retinal Diseases Caused by Rare Mutated Genes
Uni-Rare Study will improve clinical understanding of more IRDs and boost development of potential therapies.
Oct 24, 2022
Charlie Kramer: Life Coach for the Disabled
Retinitis pigmentosa (RP) runs in Charlie Kramer’s family, so it wasn’t a surprise when he was diagnosed at a young age. But now, at 29 years old, Charlie is following his passion for helping and empowering others as a full-time life coach for those with disabilities.
Oct 13, 2022
Economic Burden of Ageing Eye conditions estimated on the scale of up to billions in USA, Germany and Bulgaria
On World Sight Day 2022, Retina International is presenting data from a report on its study into the Socio-economic Impact of late-stage age-related macular degeneration (AMD) in Bulgaria, Germany, and USA.
Oct 3, 2022
Atsena’s LCA-GUCY2D Gene Therapy Improves Vision in Phase 1/2 Clinical Trial
The company is planning to move the emerging treatment into a pivotal trial
Sep 15, 2022
RD Fund Participates in a €75 Million Series B for SparingVision
Proceeds to fund first, in-human trials of breakthrough gene-agnostic therapy products and advance CRISPR-based genome editing portfolio.
Sep 8, 2022
Iveric Bio’s Zimura for Advanced Dry AMD Meets Endpoint in Second Phase 3 Clinical Trial
The company plans to seek FDA approval for the emerging therapy in first quarter of 2023
Aug 25, 2022
Belite Bio Launching Phase 3 Clinical Trial for Stargardt Disease Drug
The company’s drug is designed to reduce accumulation of toxins that cause vision loss.
Aug 15, 2022
Decades of Dedication Fighting for His Family and Himself
Dan Day is one of over ten people in his family, spanning six generations, affected with retinitis pigmentosa (RP). So to “get off the sidelines and join the fight” for himself and his family, Dan has dedicated over 25 years of service to the Foundation Fighting Blindness.